What is the primary purpose of this 10-Q/A filing?

A 10-Q/A filing is an amendment to a previously filed 10-Q quarterly report. Its purpose is generally to correct errors, provide additional information, or update previously disclosed material. In this case, the filing indicates that Exhibit 31.1 has been filed, which typically pertains to CEO/CFO certifications, suggesting a focus on ensuring the accuracy of those certifications or related disclosures.

Does this filing provide new financial performance data for Boston Scientific?

Based on the provided excerpt, this filing is primarily procedural. It indicates an amendment and lists an exhibit. Therefore, it does not directly present new financial performance data or operational updates. Investors should refer to the original 10-Q filing for the first quarter of 2013 for detailed financial results.

What is Exhibit 31.1?

Exhibit 31.1 in a 10-Q filing typically contains the certifications of the principal executive officer and principal financial officer of the company regarding the accuracy of the financial report and the effectiveness of disclosure controls and procedures. The inclusion of this exhibit with an amendment suggests a focus on these certifications.

Where can I find the actual financial results for the quarter ending March 30, 2013?

You would need to locate the original 10-Q filing for Boston Scientific Corporation for the period ending March 30, 2013. This amendment (10-Q/A) serves to modify or supplement that original report, not replace it entirely with new performance information.

BSX 10-Q Quarterly Report Q1 FY2013 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) filed an amendment to its 10-Q filing on May 6, 2013, for the period ending March 30, 2013. While the provided excerpt is limited to exhibit information, indicating the filing of an amendment (likely due to corrections or additions to previously submitted information), investors should note that this filing amendment itself doesn't present new operational or financial performance data. The primary purpose of this amendment is procedural, ensuring the accuracy and completeness of the SEC filing. Investors should refer to the original 10-Q filing for the detailed financial performance, operational updates, and forward-looking statements for the first quarter of 2013.

Financial Highlights

51 data points

Beta

Revenue

$1.76B

0.7% Gross Margin

Net Income

-$354.00M

-0.2% Net Margin

EPS (Diluted)

$-0.26

Total Assets

$16.76B

Cash & Equivalents

$268.00M

Free Cash Flow

$134.00M

Financial Statements

Beta

Revenue	$1.76B
Cost of Revenue	$578.00M
Gross Profit	$1.18B
SG&A Expenses	$631.00M
Operating Expenses	$1.51B
Operating Income	-$330.00M
Interest Expense	$65.00M
Net Income	-$354.00M
EPS (Basic)	$-0.26
EPS (Diluted)	$-0.26
Shares Outstanding (Basic)	1.35B
Shares Outstanding (Diluted)	1.35B

Key Highlights

1This filing is an amendment (10-Q/A) to Boston Scientific's quarterly report for the period ending March 30, 2013.
2The amendment was filed on May 6, 2013, indicating a subsequent review or update to the original filing.
3The excerpt specifically lists Exhibit 31.1 as being filed with this amendment.
4Exhibit 31.1 typically relates to certifications by principal executive and financial officers, suggesting the amendment may involve or confirm these certifications.
5Investors should consult the original 10-Q filing for detailed financial and operational results for the quarter.
6The amendment itself does not introduce new financial performance metrics or strategic information beyond procedural corrections or confirmations.

BOSTON SCIENTIFIC CORP Quarterly Report (Amendment) for Q1 Ended Mar 31, 2013

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions